Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 3 art units • 7 examiners • 2 of 8 (25%) have an AI response strategy ready • 2 patents granted in the last 365 days
Sana Biotechnology Inc. maintains 8 pending office actions concentrated in the Biotechnology & Pharmaceuticals technology area. The portfolio is under review by 7 distinct examiners, which suggests that most examiners are handling individual matters for the company. These examiners are situated within 3 distinct art units. The ratio of 7 distinct examiners to 3 distinct art units indicates that multiple reviewers are working within the same technical groups to process the filings currently active.
MOORE, JOHN DAVID is the busiest examiner assigned to the portfolio with 2 pending office actions. This concentration shows that while the majority of the workload is spread across various individuals, a single examiner manages 2 of the 8 pending office actions. The presence of these matters across the 3 distinct art units suggests a high degree of technical focus in the company's current prosecution efforts, even as the work is distributed among 7 distinct examiners.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 2 (25%) |
| Double-patenting + other | 2 (25%) |
| Multi-statute (no §101) | 4 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOORE, JOHN DAVID | 2 | 64.2% | +24.8% |
| CANDELARIA, JULIANA IRENE | 1 | 0.0% | +0.0% |
| BELYAVSKYI, MICHAIL A | 1 | 64.2% | +27.6% |
| GRABER, JAMES J | 1 | 46.7% | +57.7% |
| BUTTICE, AUDREY L | 1 | 47.9% | +25.9% |
| EBBINGHAUS, BRIANA NOEL | 1 | 61.6% | +63.5% |
| MCCORMICK, CATHERINE LYNN | 1 | 50.0% | +42.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18031771 | HEPATOCYTE-LIKE CELLS | EBBINGHAUS, BRIANA NOEL | 19d overdue |
| 18835218 | METHODS OF REPEAT DOSING AND ADMINISTRATION OF LIPID PARTICLES OR VIRAL VECTORS AND RELATED SYSTEMS AND USES | CANDELARIA, JULIANA IRENE | — |
| 18720534 | MODIFIED PARAMYXOVIRIDAE FUSION GLYCOPROTEINS | MOORE, JOHN DAVID | — |
| 18682798 | GENETICALLY MODIFIED CELLS FOR ALLOGENEIC CELL THERAPY | MOORE, JOHN DAVID | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18031771 | HEPATOCYTE-LIKE CELLS | EBBINGHAUS, BRIANA NOEL | 19d overdue |
| 17637789 | CD24 EXPRESSING CELLS AND USES THEREOF | MCCORMICK, CATHERINE LYNN | 63d |
| 18720534 | MODIFIED PARAMYXOVIRIDAE FUSION GLYCOPROTEINS | MOORE, JOHN DAVID | — |
| 18682798 | GENETICALLY MODIFIED CELLS FOR ALLOGENEIC CELL THERAPY | MOORE, JOHN DAVID | — |
| 18682778 | INDUCIBLE SYSTEMS FOR ALTERING GENE EXPRESSION IN HYPOIMMUNOGENIC CELLS | BELYAVSKYI, MICHAIL A | — |
| 18682797 | GENETICALLY MODIFIED CELLS FOR ALLOGENEIC CELL THERAPY TO REDUCE INSTANT BLOOD MEDIATED INFLAMMATORY REACTIONS | GRABER, JAMES J | — |
| 18561682 | HYPOIMMUNOGENIC RHD NEGATIVE PRIMARY T CELLS | BUTTICE, AUDREY L | — |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| 1632 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18835218 | METHODS OF REPEAT DOSING AND ADMINISTRATION OF LIPID PARTICLES OR VIRAL VECTORS AND RELATED SYSTEMS AND USES | CANDELARIA, JULIANA IRENE | — | §103§112 | Non-Final OA | — | Pending | Aug 01, 2024 |
| 18720534 | MODIFIED PARAMYXOVIRIDAE FUSION GLYCOPROTEINS | MOORE, JOHN DAVID | — | §103§112 | Non-Final OA | — | Pending | Jun 14, 2024 |
| 18682798 | GENETICALLY MODIFIED CELLS FOR ALLOGENEIC CELL THERAPY | MOORE, JOHN DAVID | — | §103§112 | Non-Final OA | — | Pending | Feb 09, 2024 |
| 18682778 | INDUCIBLE SYSTEMS FOR ALTERING GENE EXPRESSION IN HYPOIMMUNOGENIC CELLS | BELYAVSKYI, MICHAIL A | — | §102Other | Non-Final OA | — | Pending | Feb 09, 2024 |
| 18682797 | GENETICALLY MODIFIED CELLS FOR ALLOGENEIC CELL THERAPY TO REDUCE INSTANT BLOOD MEDIATED INFLAMMATORY REACTIONS | GRABER, JAMES J | 1631 | §103§112DP | Non-Final OA | — | Pending | Feb 09, 2024 |
| 18561682 | HYPOIMMUNOGENIC RHD NEGATIVE PRIMARY T CELLS | BUTTICE, AUDREY L | — | §103DP | Non-Final OA | — | Pending | Nov 16, 2023 |
| 18031771 | HEPATOCYTE-LIKE CELLS | EBBINGHAUS, BRIANA NOEL | 1632 | §102§103§112 | Final Rejection | 19d overdue | AI Ready | Apr 13, 2023 |
| 17637789 | CD24 EXPRESSING CELLS AND USES THEREOF | MCCORMICK, CATHERINE LYNN | 1638 | §102 | Final Rejection | 63d | AI Ready | Feb 23, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial